1. A system, comprising:
a non-transitory memory storing instructions;
one or more hardware processors coupled to the non-transitory memory and configured to read the instructions to cause the system to perform operations comprising:
determining a browser of the client device, wherein the browser is associated with a rich Internet application and a runtime platform;
causing the browser to activate the rich Internet application to run on the runtime platform;
causing an authentication library of the browser to receive information from the runtime platform;
determining the rich Internet application is authentic to secure an in-line transfer with the service provider based at least on the information received by the authentication library from the runtime platform; and
causing a user interface of the system to display a notification that indicates the rich Internet application is authentic to secure the in-line transfer with the service provider, wherein the in-line transfer with the service provider is secure without redirecting the browser to a website of the service provider that requires login information.
2. The system of claim 1, wherein the rich Internet application comprises a plurality of code segments, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining code signatures embedded in the plurality of code segments that indicate the rich Internet application is authentic to the service provider.
3. The system of claim 1, wherein the instruction cause the system to perform further operations comprising determining the information received from the runtime platform indicates a domain name of a server associated with the service provider, and wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider is further based on the domain name indicated in the information received from the runtime platform.
4. The system of claim 1, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining an amount of the information received by the authentication library from the runtime platform, wherein determining the rich Internet application is authentic comprises determining the rich Internet application is authentic to further authorize user activities with the client device based at least on the amount of information received.
5. The system of claim 4, wherein determining the rich Internet application is authentic to further authorize the user activities with the client device comprises determining the rich Internet application is authentic to communicate with the authentication library to complete in-line transfers of the user activities with the service provider.
6. The system of claim 1, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining a hash value calculated from the information received by the authentication library, wherein the hash value indicates an authentic behavior of the rich Internet application.
7. The system of claim 1, wherein the instructions cause the system to perform further operations comprising:
sending the information received to a remote server configured to verify a behavior of the rich Internet application; and
receiving a confirmation from the remote server, wherein the confirmation indicates that the rich Internet application is authentic.
8. A method, comprising:
determining, by one or more processors of a client device, a browser of the client device associated with a rich Internet application, a runtime platform, and an authentication library;
causing, by the one or more processors, the browser to activate the rich Internet application to run on the runtime platform;
causing, by the one or more processors, the authentication library to receive information from the runtime platform, wherein the authentication library is configured to authenticate the rich Internet application with a service provider;
determining, by the one or more processors, the rich Internet application is authentic to secure an in-line transfer with the service provider based at least on the information received by the authentication library from the runtime platform; and
causing, by the one or more processors, a user interface of the client device to display a notification that indicates the rich Internet application is authentic to secure the in-line transfer with the service provider, wherein the in-line transfer with the service provider is secure without redirecting the browser to a website of the service provider.
9. The method of claim 8, wherein the rich Internet application comprises a plurality of code segments, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining code signatures embedded in the plurality of code segments that indicate the rich Internet application is authentic to the service provider.
10. The method of claim 8, further comprising determining, by the one or more processors, the information received from the runtime platform indicates a domain name of a server associated with the service provider, and wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider is further based on the domain name indicated in the information received from the runtime platform.
11. The method of claim 8, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining an amount of the information received by the authentication library from the runtime platform, wherein determining the rich Internet application is authentic comprises determining the rich Internet application is authentic to further authorize user activities with the client device based at least on the amount of information received.
12. The method of claim 11, wherein determining the rich Internet application is authentic to further authorize user activities with the client device comprises determining the rich Internet application is authentic to communicate with the authentication library to complete in-line transfers associated of the user activities with the service provider.
13. The method of claim 8, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining, by the one or more processors, a hash value calculated from the information received by the authentication library, wherein the hash value indicates an authentic behavior of the rich Internet application.
14. The method of claim 8, further comprising:
sending the information received to a remote server configured to verify a behavior of the rich Internet application; and
receiving a confirmation from the remote server, wherein the confirmation indicates that the rich Internet application is authentic.
15. A non-transitory machine-readable medium having stored thereon machine-readable instructions executable to cause a machine to perform operations, comprising:
determining, based at least on a communication of the machine with a client device, a browser of a client device that comprises a rich Internet application running on a runtime platform;
receiving information from the client device, wherein the information is retrieved by an authentication library from the runtime platform;
determining the rich Internet application is authentic to secure an in-line transfer with a service provider based at least on the information received from the authentication library; and
sending a notification to the client device that indicates the rich Internet application is authentic to secure the in-line transfer with the service provider, wherein the in-line transfer is secure without redirecting the browser to a website of the service provider.
16. The non-transitory machine-readable medium of claim 15, wherein the rich Internet application comprises a plurality of code segments, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining code signatures embedded in the plurality of code segments that indicate the rich Internet application is authentic to the service provider.
17. The non-transitory machine-readable medium of claim 15, wherein the machine comprises a server of the service provider, and wherein the machine-readable instructions are executable to cause the machine to perform further operations comprising:
determining the information retrieved from the runtime platform indicates a domain name of the server, and wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider is further based on the domain name indicated in the information received from the runtime platform.
18. The non-transitory machine-readable medium of claim 15, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining an amount of the information received by the authentication library from the runtime platform, wherein determining the rich Internet application is authentic comprises determining the rich Internet application is authentic to further authorize user activities with the client device based at least on the amount of information received.
19. The non-transitory machine-readable medium of claim 18, wherein determining the rich Internet application is authentic to further authorize user activities with the client device comprises determining the rich Internet application is authentic to communicate with the authentication library to complete in-line transfers associated with the user activities with the service provider.
20. The non-transitory machine-readable medium of claim 15, wherein determining the rich Internet application is authentic to secure the in-line transfer with the service provider comprises determining a hash value calculated from the information received by the authentication library, wherein the hash value indicates an authentic behavior of the rich Internet application.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for reducing proliferation of a PPAR\u03b3-responsive hyperproliferative cell in a subject in need thereof, comprising contacting the cell with a) a PPAR\u03b3 agonist represented by the formula:
or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof
in which A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A2 represents a benzyl or chromanyl moiety having, as valence and stability permit, up to five substituents; and n represents an integer in the range of from 1 to 6
in an amount effective to reduce proliferation of the cell, and b) a second antiproliferative agent, wherein the PPAR\u03b3-responsive hyperproliferative cell is selected from the group consisting of an adipose cell, an adipose precursor cell, an adipose tumor cell, a liposarcoma cell, a myeloid cell, a hemopoietic cell, a hemopoietic precursor cell, and a prostate cancer cell.
2. The method of claim 1, wherein the PPAR\u03b3 agonist is a compound selected from the group consisting of pioglitazone, troglitazone, ciglitazone, englitozone, and BRL49653 (rosiglitazone).
3. The method of claim 1, wherein the PPAR\u03b3 agonist is BRL49653 (rosiglitazone).
4. The method of claim 1, wherein the second antiproliferative agent is selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, nucleic acid intercalating agents, topoisomerase inhibitors, agents which promote apoptosis, and agents which increase immune responses to tumor.
5. The method of claim 1, wherein the second antiproliferative agent is selected from the group consisting of cisplatin, carboplatin, and cyclophosphamide.
6. The method of claim 1, wherein the second antiproliferative agent is carboplatin.
7. The method of claim 1, wherein the cell is derived from an adipose cell or an adipose precursor cell.
8. The method of claim 1, wherein the cell is a liposarcoma cell.
9. The method of claim 1, wherein the cell is derived from an hemopoietic cell or an hemopoietic precursor cell.
10. The method of claim 9, wherein the cell is derived from malignant transformation of a cell of the lymphoid or myeloid lineage.
11. A method for reducing proliferation of a PPAR\u03b3-responsive hyperproliferative cell, comprising contacting the cell with BRL49653 (rosiglitazone) and carboplatin, wherein the PPAR\u03b3-responsive hyperproliferative cell is selected from the group consisting of an adipose cell, an adipose precursor cell, an adipose tumor cell, a liposarcoma cell, a myeloid cell, a hemopoietic cell, a hemopoietic precursor cell, and a prostate cancer cell.
12. A method treating, in a subject in need thereof, a disease or disorder characterized by unwanted proliferation of PPAR\u03b3-responsive hyperproliferative cells, comprising administering to the animal a pharmaceutical preparation of a PPAR\u03b3 agonist represented by the formula:
or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof
in which A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A2 represents a benzyl or chromanyl moiety having, as valence and stability permit, up to five substituents; and n represents an integer in the range of from 1 to 6
in an amount effective to reduce growth of the PPAR\u03b3-responsive hyperproliferative cells, wherein the PPAR\u03b3-responsive hyperproliferative cell is selected from the group consisting of an adipose cell, an adipose precursor cell, an adipose tumor cell, a liposarcoma cell, a myeloid cell, a hemopoietic cell, a hemopoietic precursor cell, and a prostate cancer cell.
13. The method of claim 12, wherein the PPAR\u03b3 agonist is a compound selected from the group consisting of pioglitazone, troglitazone, ciglitazone, englitozone, and BRL49653 (rosiglitazone).
14. The method of claim 12, wherein the PPAR\u03b3 agonist is BRL49653 (rosiglitazone).
15. The method of claim 12, further comprising administering to the subject animal, an antiproliferative agent selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, nucleic acid intercalating agents, topoisomerase inhibitors, agents which promote apoptosis, and agents which increase immune response to tumors.
16. The method of claim 12, further comprising administering to the subject animal an antiproliferative agent selected from the group consisting of cisplatin, carboplatin, and cyclophosphamide.
17. The method of claim 12, wherein the cell is derived from an adipose cell or an adipose precursor cell.
18. The method of claim 12, wherein the cell is a liposarcoma cell.
19. The method of claim 12, wherein the cell is derived from an hemopoietic cell or an hemopoietic precursor cell.
20. The method of claim 19, wherein the cell is derived from malignant transformation of a cell of the lymphoid or myeloid lineage.
21. The method of claim 12, wherein the disease or disorder comprises an adipose cell tumor.
22. The method of claim 21, wherein the adipose cell tumor is selected from the group consisting of lipomas, fibrolipomas, lipoblastomas, lipomatosis, hibemomas, hemangiomas, and liposarcomas.
23. The method of claim 21, wherein the adipose cell tumor is a liposarcoma.
24. The method of any of claims 11 or 12, wherein the disorder is selected from the group consisting of sarcoma, carcinoma and leukemia.
25. The method of claim 24, wherein the disorder comprises a leukemic cancer.
26. The method of claim 11, wherein the subject animal is a mammal.
27. The method of claim 11, wherein the subject animal is a human.